NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a
clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome, and other central nervous system (CNS) diseases, today
announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will provide a corporate overview at the Noble
Capital Markets 14th Annual Institutional Investor Conference.
Dr. Missling will also participate in a disease-specific panel, titled Central Nervous System: Is there a cure for
Alzheimer’s on the Horizon?
The corporate presentation will take place on Monday, January 29th at 3:00 p.m. EST at the W Hotel, Fort Lauderdale, FL. The
panel will take place same day on Monday, January 29th at 9 a.m. EST.
A video webcast of Anavex’s presentation will be available at www.nobleconference.com and on the Company’s web site at www.anavex.com. The video webcast will be archived on Anavex’s website following the event.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of
differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease,
other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed a successful a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73
is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical
studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant,
anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS
disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to
develop ANAVEX®2-73 for the treatment of Parkinson’s disease. The grant fully funds a preclinical study, which could
justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and
M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major
Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are
only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such statements due to various factors, including the risks set forth
in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors & Media:
Clayton Robertson
The Trout Group
(646) 378-2900
crobertson@troutgroup.com
